# Larimar Therapeutics Estimates $128.7 Million in Cash at Quarter-End

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/58314
Published: 2026-11-16T12:30:29.000Z
Updated: 2026-11-16T12:30:29.000Z
Section: Business

> The preliminary, unaudited estimate covers cash, equivalents and marketable securities as of Sept. 30, 2026. Larimar projects its cash runway into late Q2 2027.

Larimar Therapeutics, Inc. estimated it had $128.7 million in cash, cash equivalents and marketable securities at the end of September, with a projected cash runway into late Q2 2027.

The figure was preliminary and unaudited as of Sept. 30, 2026, and could change after the quarter-end close.

Larimar’s cash runway projection extends into late Q2 2027.


